Skip to main content
SpringerLink
Log in

Gastrolesività e steroidi: miti e realtà

  • RASSEGNA
  • Published:
L'Endocrinologo Aims and scope

Sommario

La profilassi con inibitore di pompa protonica (PPI) nei pazienti in concomitante trattamento steroideo o negli stati di ipercortisolismo è argomento ad oggi molto dibattuto in quanto, a differenza dell’accertato rischio trombotico correlato all’eccesso di glucocorticoidi, non ci sono dati certi sul rischio emorragico; pertanto, qualora quest’ultimo fosse assente, la profilassi con PPI, oltre a non apportare benefici gastroenterici, aumenterebbe anche il rischio di effetti collaterali correlati a questi farmaci.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Bibliografia

  1. Trementino L, Arnaldi G, Appolloni G et al. (2010) Coagulopathy in Cushing’s syndrome. Neuroendocrinology 928(Suppl 1):55–59

    Article  CAS  Google Scholar 

  2. Van Der Pas R, Leebeek FW, Hofland KJ et al. (2013) Hypercoagulability in Cushing’s syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol 78:481–488

    Article  CAS  Google Scholar 

  3. Hatipoglu E, Caglar AS, Caglar E et al. (2015) Peptic ulcer disease in endogenous hypercortisolism: myth or reality? Endocrine 50(2):489–495

    Article  CAS  PubMed  Google Scholar 

  4. Garcia Rodríguez LA, Hernández-Díaz S (2001) The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res 3(2):98–101

    Article  PubMed  Google Scholar 

  5. Weil J, Langman MJ, Wainwright P et al. (2000) Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 46(1):27–31

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Dorlo TP, Jager NG, Beijnen JH, Schellens JH (2013) Concomitant use of proton pump inhibitors and systemic corticosteroids. Ned Tijdschr Geneeskd 157(19):A5540

    PubMed  Google Scholar 

  7. Conn HO, Blitzer BL (1976) Non association of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 294(9):473–479

    Article  CAS  PubMed  Google Scholar 

  8. Conn HO, Poynard TJ (1994) Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. Int Med 236(6):619–632

    Article  CAS  Google Scholar 

  9. Conn HO, Poynard T (1984) Adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 310(3):201–202

    Article  CAS  PubMed  Google Scholar 

  10. Narum S, Westergren T, Klemp M (2014) Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open 4(5):e004587

    Article  PubMed  PubMed Central  Google Scholar 

  11. Messer J, Reitman D, Sacks HS et al. (1983) Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 309(1):21–24

    Article  CAS  PubMed  Google Scholar 

  12. Guslandi M (2013) Steroid ulcers: any news? World J Gastrointest Pharmacol Ther 4(3):39–40

    Article  PubMed  PubMed Central  Google Scholar 

  13. Butler E, Møller MH, Cook O et al. (2018) Corticosteroids and risk of gastrointestinal bleeding in critically ill adults: Protocol for a systematic review. Acta Anaesthesiol Scand 62(9):1321–1326

    Article  CAS  PubMed  Google Scholar 

  14. Martínek J, Hlavova K, Zavada F et al. (2010) “A surviving myth”—corticosteroids are still considered ulcerogenic by a majority of physicians. Scand J Gastroenterol 45(10):1156–1161

    Article  PubMed  Google Scholar 

  15. Munson JC, Wahl PM, Daniel G et al. (2012) Factors associated with the initiation of proton pump inhibitors in corticosteroid users. Pharmacoepidemiol Drug Saf 21(4):366–374

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Chrousos GA, Kattah JC, Beck RW, Cleary PA (1993) Side effects of glucocorticoid treatment. Experience of the optic neuritis treatment trial. JAMA 269(16):2110–2112

    Article  CAS  PubMed  Google Scholar 

  17. Caplan A, Fett N, Rosenbach M et al. (2017) Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Gastrointestinal and endocrinologic side effects. J Am Acad Dermatol 76(1):11–16

    Article  PubMed  Google Scholar 

  18. Brouwer MC, McIntyre P, Prasad K, van de Beek D (2015) Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 9:CD004405

    Google Scholar 

  19. Alderson P, Roberts I (2005) Corticosteroids for acute traumatic brain injury. Cochrane Database Syst Rev 1:CD000196

    Google Scholar 

  20. Annane D, Bellissant E, Bollaert PE et al. (2015) Corticosteroids for treating sepsis. Cochrane Database Syst Rev 12:CD002243

    Google Scholar 

  21. Zilio M, Mazzai L, Sartori MT et al. (2016) A venous thromboembolism risk assessment model for patients with Cushing’s syndrome. Endocrine 52(2):322–332

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinica di Endocrinologia e Malattie del Metabolismo, Università Politecnica delle Marche, Ospedali Riuniti di Ancona, Ancona, Italia

    Giulia Giancola & Giorgio Arnaldi

Authors
  1. Giulia Giancola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giorgio Arnaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giorgio Arnaldi.

Ethics declarations

Conflitto di interessi

Gli autori Giulia Giancola e Giorgio Arnaldi dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi su animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Additional information

Proposto da Giorgio Arnaldi.

Materiale elettronico supplementare

I link al materiale elettronico supplementare sono elencati qui sotto.

(DOC 27 kB)

(DOC 26 kB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giancola, G., Arnaldi, G. Gastrolesività e steroidi: miti e realtà. L'Endocrinologo 20, 153–160 (2019). https://doi.org/10.1007/s40619-019-00584-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-019-00584-3

Parole chiave

Search

Navigation